About US
Contact us
-
J&J does a quick about-face on $1B media account moveApparently you can go home again. Just a year after switching U.S. media buying partners, Johnson & Johnson ($JNJ) is taking its $1 billion media account back to J3, a J&J-dedicated unit insid2015/9/15
-
Takeda gets enough takers to complete $2.3B Actos settlementA month ago it appeared likeTakedamight not get enough takers to move forward with its sweeping $2.3 billion offer to settle thousands of claims over the cancer risks of diabetes drugActos. But over t2015/9/15
-
Why is Novartis' Copaxone copy lagging? It's all about coverage, analyst explainsTypically, the first generics for blockbuster meds get off to a running start. Not so with Novartis' ($NVS) generic of Teva's ($TEVA) multiple sclerosis standoutCopaxone, though--and Bernstein analyst2015/9/14
-
Just wait, Perrigo investor urges. We can get the same return--without a Mylan dealAll eyes are on Perrigo's investors, who will have to decide whether to accept Mylan's offer when the wannabe acquirer takes it to them next Monday. And Israeli businessman Mori Arking, for one, plans2015/9/11
-
Horizon steps up its official Depomed pursuit with campaign websiteHorizon Pharma($HZNP)has officially begun mailing solicitation materials to shareholders of unwilling M&A target Depomed($DEPO), including a letter related to its efforts to call the two special m2015/9/11
-
Cost watchdog says PCSK9 meds should cost 85% less. Realistic or not?Payers ready to balk at the cost of new cholesterol-fighting PCSK9 drugs could have some new backing. A not-for-profit drug pricing watchdog, which analyzed data on the drugs, says they should cost on2015/9/10
-
Icahn casts his eye on Vivus with tender offer for convertible notesActivist investor Carl Icahn is jumping into the biopharma fray once again, this time getting involved with struggling obesity drugmaker Vivus. On Wednesday, his Icahn Enterprises offered to buy up a2015/9/10
-
Already riding naloxone boom, Amphastar plots nasal spray to rival old formulasA surge ofopioid-related deaths in the U.S. has created an opportunity for pharma companies that make the overdose antidotenaloxone. The drug's price has risen tenfold in recent years,Bloombergreports2015/9/9
-
Novartis CEO: Payers not sold on performance pricing yet, but that'll changeNovartis ($NVS) CEO Joe Jimenez sees a couple of rays of hope for drug spending--and for the viability of higher-priced meds. Big Data, for one. And performance-based pricing for another. In an inter2015/9/9
-
UPDATED: AstraZeneca scores FDA nod for long-term Brilinta useAstraZeneca's ($AZN) blood thinnerBrilintais officially one step closer to living up to the $3.5 billion ambitions the British pharma laid out last February. TheFDAhas handed down an approval for long2015/9/7